Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine ... Spravato, which is derived from ketamine, is not a new drug—it first ...
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...